Medication compliance and disease exacerbation in patients with asthma: a retrospective study of managed care data.

BACKGROUND Compliance with asthma medications probably results in improved outcomes, but few studies have examined this relationship. OBJECTIVE To examine the association between medication compliance and exacerbation in asthmatic patients. METHODS Retrospective analysis of a managed care database. The 97,743 participants (aged 6-99 years; mean age, 32.8 years) had asthma and prescriptions for controller medications. Compliance with the index medication (the first controller medication prescribed) was measured using 2 methods: medication possession ratio (MPR), calculated for 365 days after the index date, and number of prescriptions for each index medication. Exacerbation was defined as 1 or more emergency department visits or hospitalizations within 1 year of the index date. Multivariate models were used to determine the odds of exacerbation based on relative compliance for each definition of compliance. RESULTS Based on the median MPR, more-compliant patients were less likely to experience exacerbation than less-compliant patients (odds ratio, 0.94; 95% confidence interval, 0.91-0.97; P < .001). Using the 75th percentile MPR, risk of exacerbation was even smaller (odds ratio, 0.89; 95% confidence interval, 0.86-0.92; P < .001). All the cutoff points for compliance (> or = 2 through > or = 6 prescriptions) demonstrated significantly less exacerbations in more-compliant vs less-compliant patients after adjusting for covariates. As the criteria for compliance became more stringent, more-compliant patients became increasingly less likely to have an exacerbation vs less-compliant patients. CONCLUSION More-compliant asthmatic patients were significantly less likely to experience exacerbation than less-compliant asthmatic patients. These findings demonstrate the importance of improving medication compliance among asthmatic patients to impact outcomes.

[1]  T. Creer,et al.  Medication compliance and asthma: overlooking the trees because of the forest. , 1996, The Journal of asthma : official journal of the Association for the Care of Asthma.

[2]  D. King,et al.  COPD: management of acute exacerbations and chronic stable disease. , 2001, American family physician.

[3]  S. Adlis,et al.  Comparison of patients' compliance with prescribed oral and inhaled asthma medications. , 1994, Archives of internal medicine.

[4]  J. L. Rau,et al.  Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. , 2005, Chest.

[5]  Charles A. Johnson,et al.  Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. , 2004, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[6]  M. Zwarenstein,et al.  Risk factors for childhood asthma and wheezing. Importance of maternal and household smoking. , 1996, American journal of respiratory and critical care medicine.

[7]  Benay Johnson,et al.  Using a matrix as an educational approach to asthma. , 2003, Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners.

[8]  Sean D Sullivan,et al.  Asthma in the United States: recent trends and current status. , 2003, Journal of managed care pharmacy : JMCP.

[9]  A. Lahdensuo,et al.  Is asthma self-management cost-effective? , 1997, Patient education and counseling.

[10]  F. Frech,et al.  Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting , 2003, Journal of managed care pharmacy : JMCP.

[11]  D. Petitti,et al.  Asthma population management: development and validation of a practical 3-level risk stratification scheme. , 2004, The American journal of managed care.

[12]  J. Kemp,et al.  Management of asthma in children. , 2001, American family physician.

[13]  G. Skrepnek,et al.  Epidemiology, clinical and economic burden, and natural history of chronic obstructive pulmonary disease and asthma. , 2004, The American journal of managed care.

[14]  J. C. Carranza Rosenzweig,et al.  Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. , 2004, The Journal of allergy and clinical immunology.

[15]  A. Chuchalin,et al.  Evaluation of different inhaled combination therapies (EDICT): a randomised, double-blind comparison of Seretide (50/250 microg bd Diskus vs. formoterol (12 microg bd) and budesonide (800 microg bd) given concurrently (both via Turbuhaler) in patients with moderate-to-severe asthma. , 2002, Respiratory medicine.

[16]  N. Hampson,et al.  Reduction in patient timing errors using a breath-activated metered dose inhaler. , 1994, Chest.

[17]  A. Perwien,et al.  Stimulant Treatment Patterns and Compliance in Children and Adults With Newly Treated Attention-Deficit/Hyperactivity Disorder , 2004, Journal of managed care pharmacy : JMCP.

[18]  K. Gendo,et al.  Asthma economics: focusing on therapies that improve costly outcomes , 2005, Current opinion in pulmonary medicine.